EBS Technologies develops medical devices and innovative therapeutic applications for the treatment of neurological disorders caused by stroke or brain injury.
The aim is to achieve neurological recovery by activating residual brain structures through enhancing synaptic transmission and brain synchronization with non-invasive, pulsed electrical stimulation. The EBS NEXT WAVE™ therapy leads to normalization of deficits in vision and speech.
The EBS approach fills a great medical need as there are currently only few therapeutic solutions for treating disabilities after stroke and brain trauma. The market offers training procedures, such as vision or speech training. As those procedures do request a high compliance from the patient there is a strong demand for low-risk and easy to apply therapy technologies that significantly support the rehabilitation process.
The company benefits from more than 15 years of research of the founders and clinical experience with more than 1.000 patients (observational studies).
EBS has developed a NEXT WAVE™ prototype device for non-invasive electrical stimulation that has been and is currently used for clinical trials.